MoonLake Immunotherapeutics (MLTX) Institutional Ownership

Ownership Summary

A total of 2 institutions have reported a stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) as of December 2025, according to recent 13F filings with the SEC.

• These investors collectively held 0.1% of the company's total shares outstanding in December 2025, down from 61.1% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 2.30%, with a year-over-year a decrease of 98.31% in the count of filers.
• Among the 2 institutional holders of MoonLake Immunotherapeutics, 1 added to their stakes while 1 trimmed their positions and 0 held steady.
• The aggregate institutional position in MoonLake Immunotherapeutics now stands at 92.98K shares as of December 2025, after investors increased their holdings (up by 2.09K shares quarter on quarter which is down 63.09Mn shares year over year).
• CONGRESS ASSET MANAGEMENT CO continues to be the largest institutional holder of MoonLake Immunotherapeutics as of December 31, 2025, with a position of 71.10K shares, representing 0.11% of the company's outstanding stock.
• Among the most significant buyers of MoonLake Immunotherapeutics during December 2025 were SG Americas Securities, LLC (4.36K).
• Leading sellers of MoonLake Immunotherapeutics stock in December 2025 included CONGRESS ASSET MANAGEMENT CO (2.27K).
• The top 2 institutional holders of MoonLake Immunotherapeutics for the quarter ending December 2025 included CONGRESS ASSET MANAGEMENT CO (71.10K), SG Americas Securities, LLC (21.89K).